<?xml version="1.0" encoding="UTF-8"?>
<p>Ingavirin, a drug developed in Russia, adds on the current list of influenza-limiting antivirals due to its direct interference with the transportation of newly synthesized viral NP [
 <xref rid="B122-vaccines-07-00053" ref-type="bibr">122</xref>,
 <xref rid="B123-vaccines-07-00053" ref-type="bibr">123</xref>,
 <xref rid="B124-vaccines-07-00053" ref-type="bibr">124</xref>]. As of 2017, Ingavirin has been approved for the treatment of influenza and other viral causes of acute respiratory illness, in Russia, following the completion of phase IV trial. 
</p>
